19 May 2023 • A new study has found that a once-weekly insulin called icodec could be an effective treatment option for people with long-standing type 2 diabetes. The research compared icodec with the commonly used daily insulin glargine U100. The study, called ONWARDS 4, included 582 participants from nine countries. After 26 weeks, both groups showed similar improvements in blood sugar control, with a reduction in HbA1c levels. Importantly, the icodec group required fewer injections of basal insulin and had lower doses of bolus insulin. The incidence of hypoglycemia, a common side effect of insulin therapy, was similar between the two groups. The trial demonstrated the safety and efficacy of icodec, offering hope for a more convenient treatment option for people with type 2 diabetes.

Source: The Lancet | Read full story